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AGMATINE AND AGMATINE ANALOGS IN

tance is that patients often become refractory to a drug over
time. In addition, many anti-epileptic agents cause unWanted

THE TREATMENT OF EPILEPSY, SEIZURE,

side effects, neurotoxicities, and drug interactions. Even

AND ELECTROCONVULSIVE DISORDERS

While being treated With one or a combination of the anti

CROSS REFERENCE TO RELATED
APPLICATIONS

epileptic drugs currently in clinical use, 30% of epileptic
patients still experience seizures. As more anti-epileptic
drugs are developed, the clinician Will have expanded phar

This application claims priority from US. Provisional
Patent Application Ser. No. 60/211,532, ?led Jun. 15, 2000

maceutical options When designing an effective treatment

entitled “AGMATINE AND AGMATINE ANALOGS IN

THE TREATMENT OF EPILEPSY, SEIZURE, AND

US. Pat. No. 5,677,349 to Gilad et al. discloses methods
for treating neurotrauma or neurodegenerative disease in a

ELECTROCONVULSIVE DISORDERS” the entire disclo
sure of Which is incorporated herein by reference.

Neurotrauma and neurodegeneration are terms denoting the

protocol for each patient.

human by administering agmatine (4-aminobutylguanidine).
loss of cells in the brain resulting from an external trauma or

FIELD OF THE INVENTION

an external invasive procedure. Examples of neurodegenera
tion disorders include, for instance, Alzheimer’s disease and

The present invention relates to the use of agmatine and

Parkinson’ s disease, Which result from the decline of neurons

analogs thereof in the prevention and treatment of epilep sies,
seizures, and other electroconvulsive disorders.

in the substantia nigra that produce dopamine. The neurode

generative disorder, amyotrophic lateral sclerosis (ALS),
20

BACKGROUND OF THE INVENTION

tary movement. Treatment modalities for epilepsy, hoWever,
attenuate neuronal activity, i.e., regulate the over stimulation

Epilepsy is a general term describing brain disorders that
are characterized by the occurrence of seizures. Epilepsy
affects millions of people WorldWide, and over 2.5 million
individuals in the United States. For the purposes of clinical

25

orders.

type of seizure the patient experiences.
As described in The Pharmacological Basis of Therapeu
basis of therapeutics. 9th ed. 1996, NeW York: McGraW-Hill
Health Professions Division. xxi, 1905, Chapter 20). Over 30
types of epileptic seizures have been described, and they can
be generally classi?ed into tWo groupsipartial seizures (be
ginning focally in a cortical site) or generalized seizures
(involving both brain hemispheres from the outset). Partial

Accordingly a continuing need exists for pharmaceutical
30

35

40

Hundreds of epileptic syndromes have been de?ned as

disorders characterized by speci?c symptoms that include
epileptic seizures. These epileptic syndromes include, but are
not limited to, absence epilepsy, psychomotor epilepsy, tem

Additional advantages and features of the invention Will be
set forth in part in the description Which folloWs and in part
Will become apparent to those having ordinary skill in the art
upon examination of the folloWing or may be learned from the
practice of the invention. The advantages of the invention may
be realized and obtained as particularly pointed out in the

appended claims.
According to the present invention, the foregoing objects

50

and advantages are achieved in part by a pharmaceutical
composition for the treatment or prevention of electroconvul
sive disorders comprising (i) an effective amount of agma
tine, an agmatine analog, or a pharmaceutically acceptable
salt, complex or congener thereof and (ii) a pharmaceutically

acceptable carrier. Embodiments of the present invention
include a pharmaceutical composition comprising a dose of
about 0.1 mg/kg to about 300 mg/kg of agmatine or its phar

tile epilepsy.
A patient may suffer from any combination of different

maceutically acceptable salt.

types of seizures. Partial seizures are the most common type,

and account for approximately 60% of all seizure types.

An advantage and object of the present invention is a phar
maceutical composition useful for the treatment, prevention
and/or amelioration of disorders related to and including epi
lepsy, seizure and other electroconvulsive disorders.

45

poral lobe epilepsy, frontal lobe epilepsy, occipital lobe epi
lepsy, parietal lobe epilepsy, Lennox-Gastaut syndrome, Ras
mussen’s encephalitis, childhood absence epilepsy, Ramsay

Hunt syndrome type II, benign epilepsy syndrome, benign
infantile encephalopathy, benign neonatal convulsions, early
myoclonic encephalopathy, progressive epilepsy, and infan

compositions that treat or prevent epilepsy and its associated
symptoms With minimal side-effects.
SUMMARY OF THE INVENTION

seizures include simple partial, complex partial and partial
With secondarily generalized tonic-clonic seizures. General
ized seizures include absence, myoclonic, atonic, tonic,
clonic, and tonic-clonic (grand mal) seizures.

of the neuronal processes that control brain function rather
than treat cell death. Thus, it is believed that Gilad et al. have
not recognized the use of agmatine in the treatment or pre

vention of epilepsy, seizure, and other electroconvulsive dis

assessment, it is useful to classify patients according to the
tics, seizures can occur periodically or unpredictably. (Good
man, L. S., et al., Goodman & Gilman's Thepharmacological

results from the degeneration of neurons that control volun

55

Another object of the present invention is a method of

Regardless of the type of epilepsy, seizures signi?cantly limit
the autonomy of the patient.

treating, ameliorating, or preventing epilepsy, seizure, or

It is believed that the characteristic seizures of epilepsy are

Embodiments of the present invention include administering
a pharmaceutical composition comprising an effective

electroconvulsive disorders in a subject in need thereof.

caused by the disordered, synchronous and rhythmic ?ring of

brain neurons. The neurons can ?re at up to four times their 60 amount of agmatine, an agmatine analog, or a pharmaceuti
normal rate. As a result, epileptic seizures are an over stimu
cally acceptable salt thereof in a dose of about 0.1 to about

lation of the normal neuronal processes that control brain
function.

500 mg of the active agent per kilogram of a human subject’s
Weight inde?nitely or until symptoms associated With the

Anti-epileptic drugs are available for treating epilepsies,
but these agents have a number of shortcomings. For instance,
the agents are often poorly soluble in aqueous and biological
?uids or are extremely hygroscopic. Of even greater impor

condition or disorder cease. Additional embodiments of the
65

present invention include identifying a human subject in need
of said treatment, or prevention and preventing, or reducing

epileptic activity.

US 7,816,407 B2
4
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Although the physiological roles of agmatine are still

Additional advantages of the present invention will
become readily apparent to those skilled in this art from the

under investigation, it is evident that agmatine exerts a wide

following detailed description, wherein only the preferred

range of biological activities, including those which may

embodiment of the present invention is shown and described,
simply by way of illustration of the best mode contemplated
for carrying out the present invention. As will be realized, the
invention is capable of other and different embodiments, and
its several details are capable of modi?cations in various
obvious respects, all without departing from the present
invention.

least three possible physiological roles of agmatine have been
identi?ed. Agmatine may play a role in cell signaling, since it
interacts with (x2-adrenergic, imidaZoline and N-methyl-D
aspartate (NMDA) receptors. (Li, G., et al., Agmatine: an
endogenous clonidine-displacing substance in the brain, Sci
ence (1994) 263(5149):966-9; Anis, N., et al., Structure-ac

affect the function of the central nervous system (CNS). At

tivity relationships ofphilanthotoxin analogs andpolyamines
BRIEF DESCRIPTION OF DRAWINGS

on N-methyl-D-aspartate and nicotinic acetylcholine recep

tors, 1. Pharmacol. Exp. Ther. (1990) 254(3):764-73). Con
sequently, it has been hypothesiZed that agmatine may be a

FIG. 1 graphically illustrates the effective prevention of
seiZure activity in accordance with an embodiment of the

CNS

present invention.

involved in behavioral and visceral control. (Reis, D. 1. and S.

neurotransmitter or neuromodulator

in neurons

Regunathan, A gmati ne: a novel neurotransmitter? Adv. Phar
DESCRIPTION OF THE INVENTION

macol. (1998) 42:645-9; Reis, D. 1. and S. Regunathan,
Agmatine: an endogenous ligand at imidazoline receptors

The present invention relates to agmatine (Scheme 1), a
naturally occurring compound, and to novel congeners, ana

20

Syst. (1998) 72(2-3):80-5).

logs, and derivatives thereof, medicating compositions con
taining them, and the use thereof, especially in the prevention

Another physiological role of agmatine is that of regulating

polyamine synthesis. By inducing the synthesis of antiZyme,

and/ or treatment of all types of seiZures and other electrocon

vulsive disorders. Agmatine is an amine that is biosyntheti

may be a novel neurotransmitter in brain. 1. Auton. Nerv.

agmatine inhibits the enZyme ornithine decarboxylase, the
25

cally derived from the decarboxylation of L-arginine by argi
nine decarboxylase (ADC) (See Scheme 1).

rate-limiting enZyme in polyamine biosynthesis. (Satriano,
1., et al., Agmatine suppresses proliferation by frameshift
induction ofantizyme and attenuation ofcellularpolyamine
levels, 1. Biol. Chem. (1998) 273(25):15313-6). Polyamines
exert a wide range of activities in numerous organ systems,

Scheme 1

30

O

NH

NMDA, nicotinic, and benZodiaZepine receptors), and have
antiplatelet, anti-in?ammatory, and anticoagulant activity. In

Arginine

Decarboxylase
HO

1

NH

NH;

including the central nervous system. Polyamines regulate
cell proliferation, modulate postsynaptic receptors (such as
addition, agmatine is a competitive inhibitor of nitric oxide

NHz

35

co2

polyamine formed by decarboxylation of arginine, Biochem.

NH

1. (1996) 316(Pt 1):247-9). The cell signaling and ncuro
modulatory properties of nitric oxide have been extensively

HZN\/\/\ NH
Agmatine

NHZ

40

reviewed. (Kerwin, 1. E, et al., Nitric oxide: a new paradigm

45

for second messengers, 1. Med. Chem. (1995) 38(22):4343
62; MacMicking, 1., et al., Nitric oxide and macrophage
function, Ann. Rev. Immunol. (1997) 15:323-50; Stuehr, D.
1., Structure-function aspects in the nitric oxide synthases,
Ann. Rev. Pharmacol. Toxicol. (1997) 37:339-59).

The presence of agmatine in plants, bacteria, and lower life
forms has been well established. Agmatine and ADC-cata

lyZed agmatine biosynthesis have also been detected in higher
organisms, and are present in the brain, liver, kidney, adrenal
gland, and small intestine of mammals. (Li, G., et al., Agma

After experimentation and investigation, it was discovered
that administration of exogenous agmatine to rats resulted in

profound and reproducible anticonvulsant or antiepileptic

tine: an endogenous clonidine-displacing substance in the

brain. Science (1994) 263(5149): 966-9; Lortie, M. 1., et al.,
A gmatine, a bioactive metabolite ofarginine production, deg
radation, andfunctional e?‘ects in the kidney ofthe rat, 1. Clin.
Invest. (1996) 97(2): 413-20; Morrissey, 1., et al., Partial
cloning and characterization ofan arginine decarboxylase in
the kidney, Kidney Int. (1995) 47(5): 1458-61; Sastre, M., et
al., Metabolism ofagmatine in macrophages: modulation by
lipopolysaccharide and inhibitory cytokines, Biochem. 1.
(1998) 330(Pt 3): 1405-9). Agmatine has been detected in
several types of human cells, including astrocytes, macroph

activity in animal models of seiZure disorders. It was further
50

and other organ systems, no toxic effects were observed in
any of the animal studies as a result of the systemic adminis

tration of agmatine.
55

60

blood vessels: a novel system inhibiting vascular smooth
muscle proliferation, 1 . Pharmacol. Exp. Ther. (1996) 276(3):

1272-82; Regunathan, S., et al., Agmatine (decarboxylated
arginine) is synthesized and stored in astrocytes, Neuroreport
(1995) 6(14): 1897-900). These results are signi?cant, as they
indicate that mammalian agmatine is endogenously derived,

discovered that, despite the integral role that agmatine
appears to play in the function of the central nervous system

ages, endothelial cells and vascular smooth-muscle cells (Re

gunathan, S., et al., Imidazoline receptors and agmatine in

and not of dietary or bacterial origin.

synthase isoenZymes. (Galea, E., et al., Inhibition ofmamma
lian nitric oxide synthases by agmatine, an endogenous

L-Arginine

65

These discoveries contributed to the present invention

where it is contemplated that a human subject suffering from
or susceptible to epilepsy, seiZure and other electroconvulsive
disorders can be treated by administering a pharmaceutical
composition including an effective amount of agmatine, an
agmatine analog, or a pharmaceutically acceptable salt
thereof to treat, reduce, or prevent the disorder in the subject.
In one aspect of the present invention, a human subject is
identi?ed as having or being susceptible to the disorder prior
to the administration of the active agent.
The diagnosis of a human subject that is susceptible or in
need of such treatment is well known in the medical arts and

includes, for example, genetic analysis, electrophysiological

US 7,816,407 B2
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analysis, genealogy, etc. The diagnosis can include obtaining
and analyzing a potential human subject’s electroencephalo

ment of the present invention, agmatine and agmatine analogs
are provided by Formula I beloW:

gram (EEG), as is knoWn in the art, to determine the suscep
tibility of seizure or the actual occurrence of a seizure. The
Formula I

diagnosis can also include observing the characteristic mani
festations, symptoms, or features associated With the various
forms of epileptic seizures. The observation can be made by

R IRZN

NR3

the subject himself or herself, a medical practitioner or any

other observer capable of making such observations and
determinations. Illustrative characteristic features of various
epileptic seizures are presented in Table 1 below.

10

Wherein n is 0 to about 10; R1, R2, R3, R4, and R5, are each
independently, or any combination thereof: hydrogen,
hydroxy, substituted or unsubstituted C HO alkyl, substituted
or unsubstituted C3_8 cycloalkyl, substituted or unsubstituted

TABLE 1
SEIZURE
TYPE

Simple
partial

arylalkyl (comprising Ari(CH2)m; WhereAr is aromatic and
FEATURES

m is 0 to about 10) substituted or unsubstituted C MO alkoxyl,
substituted or unsubstituted C 1_ 1 O acyl, halogeno, amido, phe

Diverse manifestations determined by the region of cortex
activated by seizure (e. g., if motor cortex representing left
thumb, clonic jerking of left thumb results; if

nyl, thio, amino, or nitro including racemic, diastereomeric,

somatosensory cortex representing left thumb, paresthesias

partial

of left thumb results), lasting approximating 20 to 60
seconds. A key feature is preservation of consciousness.
Impaired consciousness lasting about 30 seconds to about
one to about tWo minutes, often associated With purposeless

Partial With
secondarily

movements such as lip smacking or hand wringing.
Simple or complex partial seizure evolves into a tonic
clonic seizure With loss of consciousness and sustained

generalized
tonic-clonic

contractions (tonic) of muscles throughout the body
followed by periods of muscle contraction alternating With

seizure

periods of relaxation (clonic), typically lasting about 1 to 2

Complex

20

each independently: O, NH, CH2, CF2, Se, C:O, C:N,
C:S, or S; or XiY together is HC:CH, CEC, N:N,
N:CH, CH:N, or a saturated or unsaturated ring including

all geometric and stereoisomers thereof.
In an embodiment of the present invention, XiY is a

saturated ring including, but not limited to: cyclobutane,

cyclopentane, cyclohexane, cycloheptane, cyclooctane, azet

minutes.

Absence

Abrupt onset of impaired consciousness associated With

seizure

starting and cessation of ongoing activities typically lasting

Myoclonic

A brief (perhaps a second), shock-like contraction of

seizure

muscles Which may be restricted to part of one extremity or

30

less than 30 seconds.

Tonic-clonic
seizure

may be generalized.
As described above for partial With secondarily generalized
tonic-clonic seizures except that it is not preceded by a

and all enantiomeric forms. In a preferred embodiment, R1
and R2 represent Rli(CH2)niR2 Where n is 3-8 and R3 and
R5 represent R3i(CH2)niR5 Where n is 3-8. X andY are

35

ine, piperdine, pyrazolidine, imidazoline, piperazine, pipra
zine, hexa-hydropyrimidine, thietane, thiophane, 1,3-dithi
olane, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4
dithiane, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, 1,3
dioxane and 1,4-oxathinin, oxetane, morpholine,
imidazoline, oxazoline, and thiazolidine, including all pos
sible substitution patterns, geometric and stereoisomers,
racemic, diastereomeric and enantiomeric forms thereof.

partial seizure.

In an embodiment of the present invention, XiY is an

unsaturated hydrocarbon ring including, but not limited to

In practicing the present invention, agmatine, an agmatine
analog, or a pharrnaceutically acceptable salt, complex or
cogener thereof is formulated into a pharmaceutical prepara

tion comprising the active agent and a pharrnaceutically
acceptable carrier. It has been discovered that the inventive
compositions are useful in the prevention, palliation and/or
treatment of seizures, conduction disturbances, and electro
convulsive disorders of all types, and their manifestations
irrespective of the origin of the aliment in a subject in need
thereof including humans and other mammals. It is contem
plated that the inventive compositions can be employed for
preventing and/or treating other conduction disturbances of
the CNS, and the emotional, cognitive, and motor symptoms

benzene,
40

cyclohexene,

cycloheptene,

tution patterns, geometric and stereoisomers, racemic, dias
tereomeric, and enantiomeric forms thereof.
In an embodiment of the present invention, XiY is an

unsaturated nitrogen heterocycle, including but not limited

to, pyrrole, pyrrolidine, pyrazole, imidazole, 1,2,3-triazole,
1,2,4-triazole, pyridine, pyridazine, pyrimidine, pyrazine, tri
azine, indole, indazole, pteridine, quinoline, quinazoline,
benzodiazepine, acridine, benzimidazole, purine, iso
50

quinazoline, and isoquinoline, including all possible substi
tution patterns, geometric and stereoisomers, racemic, dias
tereomeric and enantiomeric forms thereof.
In an embodiment of the present invention, XiY is an
unsaturated oxygen heterocycle, including but not limited to

resulting therefrom.
In an embodiment of the present invention, the inventive
compositions are administered to a subject, eg a human

subject, in need thereof to prevent or treat disturbances of the
CNS, such as seizure and electroconvulsive disorders, of

cyclopentene,

cyclooctene, cyclopentadiene, including all possible substi

furan, 2,5-dihydrofuran, or pyran including all possible sub
55

stitution patterns, geometric and stereoisomers, racemic,
diastereomeric, and enantiomeric forms thereof.

either or both an acute or chronic nature, of unknoWn origin or

In an embodiment of the present invention, XiY is an

secondary to conditions such as, but not limited to: surgery,
irradiation or other manipulation of the brain and/or CNS;

unsaturated sulfur containing heterocycle, including but not

alcohol, benzodiazepine, barbiturate or other drug or chemi

60

cal WithdraWal; exposure to epileptogenic drugs and/or

sible substitution patterns, geometric and stereoisomers,
racemic, diastereomeric, and enantiomeric forms thereof.

chemicals; acute or chronic injury or trauma; stroke or cere

brovascular accident; fever; meningitis or other CNS in?am

In an embodiment of the present invention, XiY is an

mation or infection; or electroconvulsive therapy.

In practicing the present invention, agmatine, an agmatine
analog, or a pharamceutically acceptable salt thereof is for
mulated into a pharmaceutical composition. In an embodi

limited to, thiophene, 2,5-dihydrothiophene, 1,2-dithioly
lium, 1,3-dithiolylium, thiopyranylium, including all pos

unsaturated selenium containing heterocycle, including but
65

not limited to selenophene including all possible substitution

patterns, geometric and stereoisomers, racemic, diastereo
meric, and enantiomeric forms thereof.
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Suspensions, syrups, and elixirs may be used for oral
administration of ?uid unit dosage forms. A ?uid preparation
including oil may be used for oil soluble forms. A vegetable
oil such as corn oil, peanut oil, or saf?oWer oil, for example,
together With ?avoring agents, sWeeteners and any preserva
tives produces an acceptable ?uid preparation. A surfactant

In an embodiment of the present invention, XiY is an

unsaturated mixed heterocycle, including but not limited to

thiaZole, benZothiaZole, benZoxaZole, thiadiaZole, phenothi
aZine, isoxaZole, 2-oxaZoline, oxaZole and oxaZin including
all possible substitution patterns, geometrical, and stereoiso
mers, racemic, diastereomeric and enantiomeric forms
thereof.
Agmatine can be isolated from naturally occurring sources

may be added to Water to form a syrup for ?uid unit dosages.

Hydro-alcoholic pharmaceutical preparations may be used

or synthetically prepared by conventional techniques. Agma
tine analogs can be synthetically prepared by conventional

having an acceptable sWeetener such as sugar, saccharine, or
a biological sWeetener and a ?avoring agent in the form of an
elixir.

synthesis as disclosed by US. Pat. No. 5,677,349 the entire

disclose of Which is hereby incorporated by reference.

Pharmaceutical compositions for parenteral and supposi

Salt forms of agmatine and its analogs include, but are not
limited to, the following: inorganic acid addition salts such as

tory administration can also be obtained using techniques
standard in the art. Another preferred use of the compounds is
in a transdermal parenteral pharmaceutical preparation in a

hydrochloride, hydrobromide, sulfate, phosphate, and nitrate;
organic acid addition salts such as acetate, galactarate, pro

pionate, succinate, lactate, glycolate, malate, tartrate, citrate,
maleate, fumarate, methanesulfonate, salicylate, p-toluene
sulfonate, benZenesulfonate, and ascorbate; salts With acidic

mammal such as a human.
20

The above and other drugs can be present in the reservoir
alone or in combination form With pharmaceutical carriers.

amino acids such as aspartate and glutamate; the salts may be

The pharmaceutical carriers acceptable for the purpose of this

in some cases hydrates or solvates With alcohols and other

invention are the art knoWn carriers that do not adversely

solvents. Salt forms of agmatine for an agmatine analog can

be prepared by admixing the acid With agmatine for its analog
in a conventional solvent or equivalent thereof, With or With

25

out alcohols or Water.

The compounds of the present invention are useful in phar
maceutical compositions for systemic administration to
mammals including humans as a single agent, or as a primary

30

or adjunct agent With any other medication, chemical, drug or
non-drug therapy, or combination thereof.

lecithin, and the like; glycols; polyalkylene glycols; aqueous
media in the presence of a suspending agent, for example,

analogs or pharmaceutically acceptable salt thereof is to be
35

sodium carboxymethylcellulose; sodium alginate; poly(vi
nylpyrolidone); and the like, alone, or With suitable dispens
ing agents such as lecithin; polyoxyethylene stearate; and the

by continuous infusion of unspeci?ed duration, by any

like. The carrier may also contain adjuvants such as preserv

acceptable route of administration including, but not limited

to, parenteral, oral, buccal, intranasal, pulmonary, transder
mal, rectal, vaginal, intradermal, intrathecal, intravenous,

sterile Water; saline, dextrose; dextrose in Water or saline;
condensation products of castor oil and ethylene oxide com
bining about 30 to about 35 moles of ethylene oxide per mole
of castor oil; liquid acid; loWer alkanols; oils such as corn oil;
peanut oil, sesame oil and the like, With emulsi?ers such as
mono- or di-glyceride of a fatty acid, or a phosphatide, e.g.,

The aforementioned administration of agmatine, agmatine
employed acutely, or as a single dose, or administered inter
mittently, or on a regular schedule of unspeci?ed duration, or

affect the drug, the host, or the material comprising the drug
delivery device. Suitable pharmaceutical carriers include

ing stabiliZing, Wetting, emulsifying agents and the like
40

together With the penetration enhancer of this invention.
By “effective amount , therapeutic amount” or “effective
dose” is meant that amount su?icient to elicit the desired

intramuscular and/ or subcutaneous routes.

The pharmaceutical preparations can be employed in unit

pharmacological or therapeutic effects, thus resulting in

dosage forms, such as tablets, capsules, pills, poWders, gran
solutions or suspensions, oil in Water or Water in oil emulsions

effective prevention or treatment of the condition or disorder.
Thus, When treating a CNS disorder, an effective amount of a
compound is that amount suf?cient to pass across the blood

and the like, containing suitable quantities of an active ingre
dient. Topical application can be in the form of ointments,
creams, lotions, jellies, sprays, douches, and the like. For oral

brain barrier of the subject to bind to relevant receptor sites in
the brain of the subject or otherWise affect the brain. Preven
tion of the condition or disorder is manifested by delaying the

ules, suppositories, sterile parenteral solutions or suspen
sions, sterile non-parenteral solutions or suspensions oral

45
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administration either solid or ?uid unit dosage forms can be

prepared With the compounds of Formula 1.
Either ?uid or solid unit dosage forms can be readily pre

pared for oral administration. For example, the compounds

55

can be mixed With conventional ingredients such as dicalci

condition or disorder.

umphosphate, magnesium aluminum silicate, magnesium
stearate, calcium sulfate, starch, talc, lactose, acacia, methyl

The effective dose can vary, depending upon factors such
as the condition of the patient, the severity of the symptoms of
the disorder, age, Weight, and the manner in Which the phar

cellulose and functionally similar materials as pharmaceuti
cal excipients or carriers. A sustained release formulation

may optionally be used. Capsules may be formulated by
mixing the compound With a pharmaceutical diluent, Which is
inert and inserting this mixture into a hard gelatin capsule
having the appropriate siZe. If soft capsules are desired, a
slurry or other dispersion of the compound With an acceptable

onset of the symptoms of the conditions or disorder. Treat
ment of the condition or disorder is manifested by a decrease
in the symptoms associated With the condition or disorder, or
an amelioration of the recurrence of the symptoms of the

maceutical composition is administered. Typically, the effec

tive dose of compounds generally requires administering the
compound in an amount of about 0.1 to about 500 mg per

vegetable, light petroleum, or other inert oil can be encapsu

kilogram of the subject’s Weight. In an embodiment of the
present invention, the a dose of about 0.1 to about 300 mg/kg
is administered per day inde?nitely or until symptoms asso

lated by machine into a gelatin capsule.

ciate With the condition or disorder cease. Preferably about

65
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1.0 to about 50 mg per kilogram body Weight is administered
per day. The required dose is less When administered

mice are tested 0.5 hours and 4 hours after administration of

the test compound. In rats, the test compound is administered
at 30 mg/kg prior to the toxicity assessment. The rats are
tested at 0.25, 0.5, 1, 2, and 4 hours after administration of the
test compound.

parenterally.
EXAMPLES

Rotorod Test

Example 1

Toxicity in mice Weighing betWeen 20.5 and 25.5 g is
assessed using the standardized rotorod test (Dunham, M. S.
and T. A. Miya, A note on a simple apparatusfor detecting
neurological de?cit in rats and mice, J. Am. Pharm. Assoc.
Sci. Edit (1957) 46:208-209). Control mice can maintain their
equilibrium for an extended period of time When they are
placed on a 6 rpm rotation rod. Neurologically impaired

The Maximal Electroshock Seizure (MES) or
Maximal Seizure Pattern Test

The MES is an experimental model for generalized tonic
clonic seizures that identi?es compounds Which prevent sei
zure spread. The MES model is highly reproducible and has a
consistent endpoint. An advantage of this model is that the

5

behavioral and electrographic seizures are consistent With

animals cannot maintain equilibrium for one minute in each
of three successive trials.
Positional Sense Test

those observed in humans (Levy, R. H., Antiepileptic drugs.

Behavioral toxicity in rats Weighing betWeen 105 and 130

3rd Ed. 1989, NeW York: Raven Press. xxvii, 1025. p.

g is assessed by the positional sense test. In this test, one hind
leg is gently loWered over the edge of a table. If the rat

85 -102).

experiences neurological toxicity, it Will not be able to
quickly lift its leg back to a normal position.

In the MES test, the animal receives an electrical stimulus,
0.2 seconds in duration, via corneal electrodes primed With an
electrolyte solution containing an anesthetic agent. The 0.2
second stimulation is generated With 150 mA in rats at 60 Hz.
TWenty rats, Weighing betWeen 105 g and 130 g receive an

circular or zigzag gait after administration of the test com

electrical stimulus 15 minutes, 30 minutes, 1 hour, 2 hours, 4

pound. In addition, ataxia, abnormal spread of the legs, abnor

hours, 8 hours and 12 hours after oral administration of a dose

mal posture, tremor hyperactivity, lack of exploratory behav
ior, somnolence, stupor, or catalepsy can indicate

Gait and Stance Test

In the gait and stance test, neurotoxicity is indicated by a

of about 30 mg/kg of agmatine in phosphate buffered in saline
per kg of the animal. The test endpoint, electrogenic seizure,

neurotoxicity. This toxicity test Was conducted on 20 rats,

is manifested as hindlimb tonic extension. Inhibition of hind

Weighing betWeen 105 and 130 g.
In rats and mice, agmatine Was demonstrated to be devoid
of any neurological toxicity related to the assays described

limb tonic extension indicates that the test compound is able
to inhibit MES-induced seizure spread Which in turn is

indicative of antiseizure activity (Levy, R. H., Antiepileptic
drugs. 3rd Ed. 1989, NeW York: Raven Press. xxvii, 1025. p.

above. Twenty-four mice, received agmatine doses as high as
300 mg/kg. As quanti?ed by the rotorod neurotoxicity test,

85-102; Levy, R. H., et al., Antiepileptic drugs. 4th Ed. 1995,

none of these animals shoWed any evidence of behavioral or

NeWYork: Raven Press. xxv, 1120. p. 99-1 10; White, H. S., et

neurotoxicity. Similarly, agmatine shoWed no neurotoxicity

al., The early identification ofanticonvulsant activity: role of

in rats. Forty rats received either oral or intraperitoneal agma
tine at a dose of 30 mg/kg. As assessed by the positional sense

the maximal electroshock and subcutaneous pentylenetetra
zol seizure models. Ital. J. Neurol. Sci. (1995) 16(1-2):73-7).
The results of the MES test demonstrate that agmatine is
effective in preventing seizure spread in the rat. As shoWn in
FIG. 1, an oral agmatine dose of 30 mg/kg prevented seizure

and the gait and stance tests, these data suggest that agmatine
is not neurotoxic.
While the present invention has been described in connec

tion With What is presently considered to be the most practical
and preferred embodiments, it is to be understood that the

spread in 37.5% of the rats Which received a shock 0.25 hours

after agmatine administration. At 0.5 hours after agmatine
administration, 12.5% of the rats Were protected, While at 1
hour after oral agmatine administration, none of the rats Were

invention is not limited to the disclosed embodiments and
examples. It should be apparent to those of skill in the art that
various modi?cations and variations may be made to the

protected from seizure spread after receiving the electrical
stimulus. Notably, at 2, 4, and 6 hours after agmatine admin
istration, protection from MES-induced seizure spread Was
again observed as 12.5%, 75% and 25%, respectively, of the

composition and method of the present invention Without
departing from the spirit or scope of the invention. All rel
evant portions of patents and publications cited herein are
incorporated by reference in their entireties.

animals in each group. These data indicate that the oral

What is claimed is:

administration of agmatine (30 mg/kg) may have both acute

1. A method of treating, ameliorating, or preventing sei
zures associated With epilepsy in a subject in need thereof, the

(0-1 hours) and delayed (2-6 hours) inhibitory effects on
MES-induced seizure spread. Additionally, the administra
tion of intraperitoneal agmatine 4 hours before receiving an
electrical shock prevented seizure spread in 50% of rats so
treated, indicating that the protection from MES-induced sei
zures by agmatine can be observed When the compound is

method comprising:
administering a pharmaceutical composition comprising
about 0.1 to about 500 mg of agmatine or an agmatine

analog, or a pharmaceutically acceptable salt thereof per

kilogram of the subject’s Weight to treat, reduce, or
prevent seizures associated With epilepsy in the subject,
Wherein the agmatine analog has the folloWing formula

give via a route other than the oral route.

Example 2

Minimal Neurotoxicity
Toxicity in mice and rats is assessed using three screens:
the rotorod in mice, positional sense, and gait in rats. In mice,
the test compound is administered at doses of 30, 100, and
300 mg/kg prior to evaluation in the toxicity screens. The

60
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wherein n is 0 to about 10;

Wherein n is 0 to about 10;

R1, R2, R3, R4, and R5, are each independently, or any

R1, R2, R3, R4, and R5, are each independently, or any

combination thereof: hydrogen, hydroxy, substituted or
unsubstituted Cl_1O alkyl, substituted or unsubstituted
C3_8 cycloalkyl, substituted or unsubstituted arylalkyl
(comprising Ari(CH2)m; WhereAr is aromatic and m is

combination thereof: hydrogen, hydroxy, substituted or
unsubstituted Cl_1O alkyl, substituted or unsubstituted
C3_8 cycloalkyl, substituted or unsubstituted arylalkyl
(comprising Ari(CH2)m; WhereAr is aromatic and m is

0 to about 10) substituted or unsubstituted C 1_ 1O alkoxyl,
substituted or unsubstituted C MO acyl, halogeno,

0 to about 10) substituted or unsubstituted C 1_ 1O alkoxyl,
substituted or unsubstituted C MO acyl, halogeno,

amido, phenyl, thio, or amino; and
X andY are each independently: O, NH, CH2, CF2, Se,

10

C:O, C:N, or C:S, or XiY together is HC:CH,

amido, phenyl, thio, or amino; and
X and Y are each independently: O, NH, CH2, CF2, Se,
C:O, C:N, or C:S, or XiY together is HC:CH,

CEC, N:N, N:CH, CH:N, or a saturated or unsat

CEC, N:N, N:CH, CH:N, or a saturated or unsat

urated ring.

urated ring.

2. A method according to claim 1, Wherein the pharmaceu

6. A method according to claim 5, comprising identifying a
human subject in need of said treatment by analyZing an

tical composition comprises agmatine or its pharmaceutically
acceptable salt and a pharmaceutically acceptable carrier.

electroencephalogram taken of the human subject.
7. A method according to claim 5, comprising identifying a
human subject in need of said treatment by observing the

3. A method according to claim 2, Wherein the composition
is administered in a dose of about 0.1 to about 50 mg/kg per

day inde?nitely or until seiZures associated With the epilepsy.
4. A method according to claim 1, comprising preventing
or reducing seiZure activity.
5. A method of treating or preventing seiZures associated
With epilepsy in a human comprising:

occurrence of a seiZure in said subject.
20

identifying a human subject in need of said treatment or

prevention; and

cease.

25

9. A method according to claim 5, comprising preventing
or reducing seiZures associated With epileptic activity.
10. A method according to claim 5, comprising adminis
tering the effective amount of agmatine, an agmatine analog

30

tical composition.

administering about 0.1 to about 500 mg of agmatine or an

agmatine analog, or a pharmaceutically acceptable salt
thereof per kilogram of the subject’s Weight to the
human subject, Wherein the agmatine analog has the

folloWing formula

8. A method according to claim 5, comprising administer
ing the effective amount of agmatine, an agmatine analog or
a pharmaceutically acceptable salt thereof to the human sub
ject inde?nitely or until the seiZures associated With epilepsy

or a pharmaceutically acceptable salt thereof as a pharmaceu

11. A method according to claim 5, comprising adminis
tering the effective amount of agmatine, an agmatine analog
NR3
35

or a pharmaceutically acceptable salt thereof parenterally.
12. A method according to claim 5, comprising adminis
tering the effective amount of agmatine, an agmatine analog
or a pharmaceutically acceptable salt thereof orally.
*

*

*

*

*

